Tags

Type your tag names separated by a space and hit enter

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
Expert Rev Vaccines. 2003 Apr; 2(2):197-203.ER

Abstract

The need to enhance the immunogenicity of purified subunit antigens has prompted the development of several new adjuvants. However, many of these new molecules have demonstrated a reactogenicity profile that is not suitable for their inclusion in vaccines for human use. In this context, the adjuvant emulsion MF59 has been developed, tested in combination with different antigens in several animal models and subsequently evaluated in humans. Clinical trials with several MF59-adjuvanted vaccines have been performed in different age groups (from newborns to the elderly) and have shown an increased immunogenicity of coadministered antigens, associated with a high level of safety and tolerability. MF59 has been the first adjuvant to be licensed for human use after alum and, as part of an enhanced influenza vaccine for the elderly, is now available in the marketplace of several countries worldwide.

Authors+Show Affiliations

Chiron Vaccines Clinical Research & Medical Affairs, Siena, Italy. Audino_Podda@chiron.itNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12899571

Citation

Podda, Audino, and Giuseppe Del Giudice. "MF59-adjuvanted Vaccines: Increased Immunogenicity With an Optimal Safety Profile." Expert Review of Vaccines, vol. 2, no. 2, 2003, pp. 197-203.
Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines. 2003;2(2):197-203.
Podda, A., & Del Giudice, G. (2003). MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Review of Vaccines, 2(2), 197-203.
Podda A, Del Giudice G. MF59-adjuvanted Vaccines: Increased Immunogenicity With an Optimal Safety Profile. Expert Rev Vaccines. 2003;2(2):197-203. PubMed PMID: 12899571.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. AU - Podda,Audino, AU - Del Giudice,Giuseppe, PY - 2003/8/6/pubmed PY - 2003/8/28/medline PY - 2003/8/6/entrez SP - 197 EP - 203 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 2 IS - 2 N2 - The need to enhance the immunogenicity of purified subunit antigens has prompted the development of several new adjuvants. However, many of these new molecules have demonstrated a reactogenicity profile that is not suitable for their inclusion in vaccines for human use. In this context, the adjuvant emulsion MF59 has been developed, tested in combination with different antigens in several animal models and subsequently evaluated in humans. Clinical trials with several MF59-adjuvanted vaccines have been performed in different age groups (from newborns to the elderly) and have shown an increased immunogenicity of coadministered antigens, associated with a high level of safety and tolerability. MF59 has been the first adjuvant to be licensed for human use after alum and, as part of an enhanced influenza vaccine for the elderly, is now available in the marketplace of several countries worldwide. SN - 1476-0584 UR - https://www.unboundmedicine.com/medline/citation/12899571/MF59_adjuvanted_vaccines:_increased_immunogenicity_with_an_optimal_safety_profile_ L2 - https://www.tandfonline.com/doi/full/10.1586/14760584.2.2.197 DB - PRIME DP - Unbound Medicine ER -